Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing

European Journal of Clinical Pharmacology

Volumn 66, Issue 8, 2010, Pages 775-783

  Derks, Michael ^a   Abt, Markus ^a   Mwangi, Anne ^b   Meneses Lorente, Georgina ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Cholesteryl ester transfer protein; Dalcetrapib; High density lipoprotein cholesterol; QT interval

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MOXIFLOXACIN; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY MASS; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; ARRHYTHMIAS, CARDIAC; AZA COMPOUNDS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY, AMBULATORY; HEART; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; QUINOLINES; SULFHYDRYL COMPOUNDS; YOUNG ADULT;

EID: 77955554815     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0841-2     Document Type: Article

References (14)

1. PJ Barter HB Brewer Jr MJ Chapman CH Hennekens DJ Rader AR Tall 2003 Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 160 167 10.1161/01.ATV.0000054658.91146.64 1:CAS:528:DC%2BD3sXptF2jsw%3D%3D 12588754 (Pubitemid 36231923)
2. RW Clark TA Sutfin RB Ruggeri AT Willauer ED Sugarman G Magnus-Aryitey PG Cosgrove TM Sand RT Wester JA Williams ME Perlman MJ Bamberger 2004 Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib Arterioscler Thromb Vasc Biol 24 490 497 10.1161/01.ATV.0000118278.21719.17 1:CAS:528: DC%2BD2cXhvFOis7c%3D 14739125 (Pubitemid 38326143)
3. GJ de Grooth JA Kuivenhoven AF Stalenhoef J de Graaf AH Zwinderman JL Posma A van Tol JJ Kastelein 2002 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose response study Circulation 105 2159 2165 10.1161/01.CIR.0000015857.31889.7B 11994249 (Pubitemid 34517159)
4. PJ Barter M Caulfield M Eriksson SM Grundy JJ Kastelein M Komajda J Lopez-Sendon L Mosca JC Tardif DD Waters CL Shear JH Revkin KA Buhr MR Fisher AR Tall B Brewer ILLUMINATE Investigators 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 10.1056/ NEJMoa0706628 1:CAS:528:DC%2BD2sXhtlGns7bL 17984165 (Pubitemid 350146106)
5. ML Bots FL Visseren GW Evans WA Riley JH Revkin CH Tegeler CL Shear WT Duggan RM Vicari DE Grobbee JJ Kastelein RADIANCE 2 Investigators 2007 Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 153 160 10.1016/S0140-6736(07)61088-5 1:CAS:528:DC%2BD2sXns12jtLg%3D 17630038 (Pubitemid 47042895)
6. JJ Kastelein SI van Leuven L Burgess GW Evans JA Kuivenhoven PJ Barter JH Revkin DE Grobbee WA Riley CL Shear WT Duggan ML Bots RADIANCE 1 Investigators 2007 Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 1620 1630 10.1056/NEJMoa071359 1:CAS:528:DC%2BD2sXksFCmsb4%3D 17387131 (Pubitemid 46631671)
7. SE Nissen JC Tardif SJ Nicholls JH Revkin CL Shear WT Duggan W Ruzyllo WB Bachinsky GP Lasala EM Tuzcu ILLUSTRATE Investigators 2007 Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 1304 1316 10.1056/NEJMoa070635 1:CAS:528:DC%2BD2sXjsFGnsrY%3D 17387129 (Pubitemid 46513296)
8. JA Kuivenhoven GJ de Grooth H Kawamura AH Klerkx F Wilhelm MD Trip JJ Kastelein 2005 Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia Am J Cardiol 95 1085 1088 10.1016/j.amjcard.2004.12.064 1:CAS:528:DC%2BD2MXjsVensb0%3D 15842977 (Pubitemid 40544314)
9. EA Stein ES Stroes G Steiner BM Buckley AM Capponi T Burgess EJ Niesor D Kallend JJ Kastelein 2009 Safety and tolerability of dalcetrapib Am J Cardiol 104 82 91 10.1016/j.amjcard.2009.02.061 1:CAS:528:DC%2BD1MXotFCitL8%3D 19576325
10. International Conference on Harmonisation (2005) E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at: http://www.fda.gov/ RegulatoryInformation/Guidances/ucm129335.htm. Accessed 6 Oct 2009
11. J Lettieri R Vargas V Agarwal P Liu 2001 Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers Clin Pharmacokinet 40 Suppl 1 19 25 10.2165/00003088-200140001-00003 1:CAS:528:DC%2BD3MXjvVWqu7Y%3D 11352438
12. M Desai L Li Z Desta M Malik D Flockhart 2003 Variability of heart rate correction methods for the QT interval Br J Clin Pharmacol 55 511 517 10.1046/j.1365-2125.2003.01791.x 1:CAS:528:DC%2BD3sXlvFait74%3D 12814443 (Pubitemid 36783190)
13. M Malik AJ Camm 2001 Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling Drug Safety 24 323 351 10.2165/00002018-200124050-00001 1:CAS:528:DC%2BD3MXjvVakt7g%3D 11419561
14. M Derks S Fowler O Kuhlmann 2009 A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib Clin Ther 31 586 599 10.1016/j.clinthera.2009.02.011 1:CAS:528:DC%2BD1MXls1SmsrY%3D 19393849